In this issue...

Dialogues in Clinical Neuroscience

Volumn 11, Issue 4, 2009, Pages 361-362

  Lebowitz, Barry D ^a   Parikh, Rajesh ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b JASLOK HOSPITAL AND RESEARCH CENTRE   (India)

Author keywords

[No Author keywords available]

Indexed keywords

CLINICAL RESEARCH; DECISION MAKING; DOCTOR PATIENT RELATION; EDITORIAL; INFORMATION TECHNOLOGY; MEDICAL PRACTICE; METHODOLOGY; PHARMACOGENETICS;

EID: 75749089618     PISSN: 12948322     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Editorial

References (8)

1. House of Lords, Science and Technology Committee. Genomic Medicine. HL Paper 107-1. Vol. 1: Report. London: The Stationery Office Limited, 2009. http://www.publications.parliament.uk/pa/ld200809/ldselect/ldsctech/107/10702. htm. Accessed 7 July 2009.
2. Centers for Disease Control and Prevention. Good laboratory practices for molecular genetic testing for heritable diseases and conditions. Morbidity and Mortality Weekly Report (MMWR). 2009;58(No. RR-6):1-37.
3. Goldstein DB. Common genetic variation and human traits. N Engl J Med. 2009;360:1696-1698.
4. Perlis RH, Patrick A, Smoller JW, Wang PS. When is pharmacogenetic testing for antidepressant response ready for the clinic? A cost-effectiveness analysis based on data from the STAR*D study. Neuropsychopharmacology. 2009;34:2227-2236.
5. FDA News. Warfarin: Updated prescribing information. 16 August 2007.
6. FDA Alert. Carbamazepine. 12 December 2007.
7. FDA. Herceptin (trastuzumab) http://www.fda.gov/cder/foi/label/2002/ trasgen082802LB.pdf.
8. FDA. Camptosar (irinotecan) http://www.fda.gov/cder/foi/label/2005/ 020571s024,027,028lbl.pdf.